Immuno-Oncology &
Biomarker Summit
Advancing the Future of Immuno-Oncology & Biomarker Innovation
Bringing together global leaders across pharmaceutical, biotech, diagnostics and research communities to explore the next generation of immuno-oncology, biomarkers and precision medicine.
Event Overview
The 3rd Edition of the Immuno-Oncology & Biomarker Summit, hosted by Veridon Global, will be held in Basel, Switzerland, between 11 and 12 March 2027. The event will gather experts from the pharmaceutical and biotech industry, diagnostics, research organizations, CROs, academia and technology companies. After the successful holding of the previous edition in London and after valuable feedback from our delegates, speakers and partners, we have decided to move the event to Basel – the hub of the European pharma and biotech industry. The summit is going to provide a platform for exploring the latest trends and innovations in cancer research, biomarker discovery, precision medicine and immuno-oncology.
Send an Enquiry
Have questions? Fill in your details below.
A Curated Platform for Building Valuable Relationships
Contrary to large oncology congresses, the Immuno-Oncology & Biomarker Summit is designed in a way so that quality is more important than quantity. The event will host senior industry professionals in a small-sized audience providing them with an opportunity to engage in a conversation, exchange experience and establish valuable business connections. The programme will include not only presentations, panel discussions and roundtables, but also networking opportunities and pre-arranged one-to-one meetings.
The Biomarker Blueprint for Immuno Oncology
Key Areas of Focus
The programme for 2027 includes important trends in:
Why Basel?
Basel provides an ideal venue for an immuno-oncology and biomarker meeting in Europe as it is home to an abundance of pharmaceutical, biotech, diagnostic, research and life sciences organisations. It allows us to have access to a unique European pharma and biotech community bridging the Swiss, German and French life science ecosystems. Basel allows us to create a more diverse regional audience while keeping the senior-focused, tightly-packed nature of the Immuno-Oncology & Biomarker Summit intact.
Who Should Attend
The summit is targeted at senior professionals working in: Pharmaceutical & Biotechnology areas like-
Attendee Demographics
Industry-Academics Ratio
Why Attend
Exclusive Insights
Latest advances in immuno-oncology, biomarkers, and precision oncology.
Collaboration
Connect with pharma, biotech, and academic leaders.
Combination Strategies
Explore checkpoint inhibitors, ADCs, and cell therapies.
Biomarker Integration
Personalization, trial optimization, and patient selection.
Regulatory Trends
Updates on global frameworks for IO and biomarker-based therapies.
2027 Edition Speakers
From Immuno-Oncology Visionaries to Biomarker Science Pioneers
Join an exceptional lineup of leading experts and industry innovators advancing the future of cancer care. The 2027 edition will bring together influential voices from pharmaceutical and biotech companies, academic research centers, regulatory bodies, and diagnostic developers—covering the full spectrum of immunotherapy, biomarker discovery, translational research, and precision oncology.
Agenda
IMMUNO-ONCOLOGY: NEXT-GENERATION THERAPIES & TRANSLATIONAL INNOVATION
| Time | Session |
|---|---|
| 8:00 — Registration and Refreshments | |
| 8:50 | Welcome Note by Veridon Global |
| 8:55 | Opening Address by the Chairperson |
| SESSION 1: NEXT-GENERATION IMMUNOTHERAPIES & EMERGING MODALITIES | |
| 9:00 | Beyond Immune Checkpoints: The Next Wave of Immuno-Oncology |
| 9:25 | CAR-T, TCR & Next-Generation Cell Therapies in Solid Tumors |
| 9:50 | Bispecific Antibodies, ADCs & T-Cell Engagers: Expanding the IO Arsenal |
| 10:15 | Morning Refreshments, Poster Presentations & One-to-One Networking Meetings |
| 10:45 | Understanding the Tumor Microenvironment: Turning Cold Tumors Hot |
| 11:10 | Translational Research: Accelerating Bench-to-Bedside Immunotherapy |
| 11:35 | Panel Discussion: The Future of Immuno-Oncology — What Will Define the Next Decade? |
BIOMARKERS & PRECISION MEDICINE: DISCOVERY, AI & CLINICAL TRANSLATION
| Time | Session |
|---|---|
| 8:30 — Registration & Morning Coffee | |
| 8:55 | Opening Remarks by the Chairperson |
| SESSION 2: ADVANCED BIOMARKER DISCOVERY & MOLECULAR DIAGNOSTICS | |
| 9:00 | AI & Computational Biomarker Discovery for Precision Oncology |
| 9:25 | Liquid Biopsy & Circulating Biomarkers in Early Detection |
| 9:50 | Multi-Omics Integration & Spatial Biology Platforms |
| 10:15 | Networking Break & One-to-One Partnering Meetings |
| 10:45 | Companion Diagnostics (CDx) Development & Commercialization |
Download the full agenda to view all sessions, panel discussions, and networking slots.
Our Esteemed Sponsors & Exhibitors
Supported by global pharmaceutical leaders, pioneering biotechnology firms, diagnostic innovators, and research hubs shaping the future of oncology and precision medicine.
Media Partners
Collaborating with global life science publications, oncology networks, and biotech media outlets.
Past Sponsors
Trusted by industry pioneers and global pharmaceutical leaders from previous editions.
Why Sponsor?
Maximize your brand influence, present groundbreaking research, and form valuable commercial partnerships with top-tier decision-makers.
Dedicated Prime Speaking Slot
Exhibition Opportunity
One-to-One Meetings
Pre-Qualified Leads
High-Level Networking
Brand Impact
Glimpses Of Our Past Edition
Highlights from high-level keynotes, interactive panel debates, and strategic networking sessions.
What Leaders Say About IOB Summit
Perspectives from oncology researchers, precision medicine innovators, and biotech executives.
"Attending the Immuno-Oncology & Biomarker Summit was a fantastic opportunity to reconnect and get energized by the potential of new immunotherapies. The summit brought together a diverse, global community to tackle shared challenges in the field. From insightful discussions on AI and antibody engineering to the importance of regulatory mechanisms, the event offered high-level technical depth and sparked crucial conversations about the power of cross-platform collaboration. A truly valuable experience for any scientist looking for meaningful engagement and motivation."
"I wanted to thank you for the nice organization and your hospitality at the conference Monday and Tuesday. I personally appreciated the talks, exchange with the participants and the Millennium Hotel, London."
"A well-organized summit that delivered a strong line-up of expert speakers. The team was responsive and attentive throughout, and the venue provided a professional backdrop for meaningful industry dialogue."
Venue
Basel bridges Switzerland, Germany, and France, and is home to Europe's densest biotech and pharmaceutical ecosystem. Venue details will be announced soon.
Basel, Switzerland
Venue to be announced
Contact Our Team Today
Where collaborations spark and the future of Immuno-Oncology and Biomarker innovation begins.
For Speaking & Partnerships
Nikita Patankar Parab
Founder, Managing Director
nikita@veridonglobal.com
